Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...

Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Edwards Lifesciences (NYSE:EW – Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, February 4th. Analysts expect the company to announce earnings of $0.

Edwards Lifesciences Co. (NYSE:EW – Get Free Report) has been given a consensus rating of “Hold” by the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One ...

Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting ...

Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a company that specializes in innovative products and technologies for structural heart disease and critical care ...

Edwards Lifesciences EW is developing the most comprehensive structural heart disease portfolio post the sell-off of the Critical Care wing. The Surgical Structural Heart business is benefiting from ...